NCT04706468View on ClinicalTrials.gov

To Evaluate the Efficacy and Safety of TG-1000 Compared With Placebo in Adult Patients With Acute Uncomplicated Influenza Virus Infection

PHASE2CompletedINTERVENTIONAL

Enrollment

202

Participants

Timeline

Start Date

December 15, 2020

Primary Completion Date

February 15, 2022

Study Completion Date

February 15, 2022

Conditions

Influenza Virus Infection

Interventions

DRUG

TG-1000

Capsules taken orally

Trial Locations (1)

Unknown

Xiangya Hospital Central South University, Hunan

All Listed Sponsors

collaborator

R&G Pharma Studies Co.,Ltd.

INDUSTRY

lead

TaiGen Biotechnology Co., Ltd.

INDUSTRY

NCT04706468 - To Evaluate the Efficacy and Safety of TG-1000 Compared With Placebo in Adult Patients With Acute Uncomplicated Influenza Virus Infection | Biotech Hunter | Biotech Hunter